D-0555-2026 Class II Ongoing
FDA drug recall D-0555-2026 was initiated by Asclemed USA Inc. on May 14, 2026 and is designated Class II. Reason for recall: CGMP Deviations; presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the FDA acceptable intake limit. The recall status is ongoing. Affected quantity: 50 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Jun 10, 2026
- Initiation Date
- May 14, 2026
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 50 bottles
Product description
Duloxetine DR Capsules, 30 mg, 30 count bottles, Rx, Relabeled by: Enovachem Pharmaceuticals, Torrance, CA 90501, NDC 76420-634-30, Marketed by: Ajanta Pharma USA Inc.
Reason for recall
CGMP Deviations; presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the FDA acceptable intake limit.
Distribution pattern
US Nationwide.
Code information
Lot # 050725G-30 & 050725F-30, Exp Date: 06/30/2026
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0555-2026
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026